Background: Bacterial infections that are resistant to antibiotics are growing in importance for global health, and by 2050, they are expected to outnumber all other causes of death. In the practice of drug therapy, it is crucial to keep the concentration of any drug in the blood at a specific level for a long time. Drug toxicity or ineffectiveness results from blood concentrations of medications that are higher than the therapeutic level due to increased drug use. To solve these problems, in recent years, much attention has been given to developing micro/nano preparations by encapsulating antibiotics on polymeric carriers.

Methods: Sea buckthorn waste was processed in accordance with MNS 3080:1981 standard to isolate pectin. Coacervates and water-based emulsions were used to encapsulate antibiotics. Microdilution was used to test antibiotic sensitivity in accordance with the Clinical Laboratory Standard Institute (T100-S27) procedure. Results were compared between MRSA ATCC 2758 and conventional strains of Staphylococcus aureus ATCC 25923 at various dilution concentrations.

Results: Pectin is a brown powder with no smell and a sour flavor. 8.9% yield, 1.3% free carboxyl group, 3.2% methylated carboxyl group, 4.5% total carboxyl group, 3.5% ash, and 0.1% nitrogen were all present together with 71.4% esterification of pectin. The suppression of bacterial growth was found to be 0.8 times lower in a study evaluating the antibacterial activity of pectin incorporating doxycycline hyclate than in pure pectin. When compared to pure pectin, it was 33 times smaller than that of wontaxime and 1 time smaller than that of doxycycline alone. Doxycycline-hyclate-containing pectin prevented MRSA development at a concentration that was 6 times lower than that of pure pectin.

Conclusion: Pectin has a maximum yield of 1.3 during a 60-minute separation at pH 2 at a precipitation concentration ratio of 1:1.5. Pectin itself is antibacterial against MRSA.

Keywords: Pectin, Microparticles, Doxycycline hyclate, MRSA